---
title: "OrbiMed Advisors Discloses Investment at Aspen Neuroscience, Inc. with 12.3% Stake"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304700413.md"
description: "OrbiMed Advisors LLC disclosed a 12.3% beneficial ownership stake in Aspen Neuroscience, Inc., filed via Schedule 13D on Nov. 6, 2026. The investment was acquired through preferred-stock conversions linked to Aspen's IPO and the purchase of 1 million shares at $15 each. OrbiMed stated the acquisition is for financial purposes only, with no intent to take control or propose major corporate changes."
datetime: "2026-11-06T23:46:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304700413.md)
  - [en](https://longbridge.com/en/news/304700413.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304700413.md)
generator: "portal-rs"
---

# OrbiMed Advisors Discloses Investment at Aspen Neuroscience, Inc. with 12.3% Stake

**OrbiMed Advisors Discloses Investment at Aspen Neuroscience, Inc. with 12.3% Stake**

OrbiMed Advisors LLC, a registered investment adviser, reported beneficial ownership of 12.3% of Aspen Neuroscience, Inc.’s common stock, held through OrbiMed Private Investments VII, LP. In its Nov. 6, 2026, Schedule 13D, the firm said the fund acquired the shares through preferred-stock conversions tied to Aspen’s IPO and a purchase of 1 million IPO shares at $15 each. OrbiMed said it made the investment for financial purposes, not to take control of Aspen.

**Investor Intent**

OrbiMed Advisors said it bought the shares as an investment, not to control Aspen Neuroscience. It reported no current proposals for a merger, asset sale, board or management change, or other major corporate change.

**Investor's Background**

OrbiMed Advisors LLC is a Delaware limited liability company and a registered investment adviser under the Investment Advisers Act. It serves as managing member of OrbiMed Capital GP VII LLC, which is general partner of OPI VII, the limited partnership that holds the Aspen shares. Through those roles, OrbiMed Advisors shares authority to vote and dispose of the fund’s holdings.

Original SEC Filing: Aspen Neuroscience, Inc. \[ ASPE \] - SCHEDULE 13D - Nov. 06, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ASPE.US](https://longbridge.com/en/quote/ASPE.US.md)

## Related News & Research

- [ARCH Venture Partners X Discloses 12.9% Stake in Aspen Neuroscience](https://longbridge.com/en/news/304929595.md)
- [OrbiMed Advisors reports acquisition of $15 million in Aspen Neuroscience common shares](https://longbridge.com/en/news/304354913.md)
- [Aspen Neuroscience's Amended Bylaws Take Effect at IPO Closing](https://longbridge.com/en/news/304014788.md)
- [ARCH Venture Fund XIV Reports Acquisition of $18 Million in Aspen Neuroscience Common Shares](https://longbridge.com/en/news/304042044.md)
- [Jim Cramer says Nvidia’s leadership shake-up won’t derail the AI trade](https://longbridge.com/en/news/305736094.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**